| Document |
Document Title |
|
WO/2023/169546A1 |
The use of an NIR-II photothermal material in preparation of a drug for reversing multidrug resistance of cancer cells. The NIR-II photothermal material is a small organic molecule fluorophore and has near-infrared-II fluorescence emissi...
|
|
WO/2023/164940A1 |
Disclosed are an aza-phenothiazine derivative and use thereof in preparing a drug for the treatment of endometrial cancer. The structure of the derivative is represented by formula I, and the definitions of substituents are described in ...
|
|
WO/2023/168367A1 |
The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
|
|
WO/2023/164680A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditi...
|
|
WO/2023/164181A1 |
The present disclosure provides, in part, benzothia(dia)zepine compounds of formula II, and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.
|
|
WO/2023/155710A1 |
The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...
|
|
WO/2023/152255A1 |
The present invention covers fused pyrimidine compounds of general formula (I), in which R1, R2, R3, R4, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, p...
|
|
WO/2023/153739A1 |
The present invention relates to a novel compound and uses thereof and, more specifically, to a compound capable of labeling a biomolecule (e.g. nucleic acid, protein, etc.), a composition for labeling or detecting a biomolecule comprisi...
|
|
WO/2023/152346A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/154282A1 |
Provided herein are compounds and compositions thereof that may be capable of disrupting, interrupting, and/or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provide...
|
|
WO/2023/153169A1 |
The present disclosure provides an organic compound represented by general formula (1). (In general formula (1), R1 to R20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, an...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/141852A1 |
Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
|
|
WO/2023/141901A1 |
A process for producing thiolactone compounds, or geometrical isomers thereof or geometrical isomeric mixtures thereof is provided. The process avoids expensive reagents, improves yield and thus is more efficient and suitable in industry.
|
|
WO/2023/134711A1 |
Disclosed are a cyclopiperidine compound, a preparation method therefor, and a use thereof. The cyclopiperidine compound of the present invention is represented by formula I'. The cyclopiperidine compound of the present invention has a b...
|
|
WO/2023/134739A1 |
Provided in the present disclosure are a six-membered cyclothiazole compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof in the prevention...
|
|
WO/2023/134708A1 |
Provided are compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including ...
|
|
WO/2023/130878A1 |
Provided are an (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-
bipyridyl-1'(2'H)-yl)methyl)-1(oxetan-2-ylmethyl)-1H-thieno[
2,3-d]imidazole-5-carboxylic acid compound, a salt or a salt crystal of the compound, a preparation...
|
|
WO/2023/018472A9 |
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
|
|
WO/2023/133543A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2023/133229A2 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/125896A1 |
A preparation method for a compound represented by formula (I) and an intermediate thereof. The method has the advantages of mild reaction conditions, simple operation, high reaction yield, high product purity, convenience in post-treatm...
|
|
WO/2023/126951A1 |
Disclosed herein are inhibitors of autophagy-related protein-protein interactions and their use for treating an autophagy-related disease or disorder, cancer, a cytokine release syndrome (CRS) or a cytokine storm in a subject.
|
|
WO/2023/128786A1 |
A family of triazole derivatives is described. Also described is the use of these triazole derivatives in treating or preventing viral infections, such as human immunodeficiency virus (HIV) infections, and the diseases caused by these in...
|
|
WO/2023/127012A1 |
Provided is a therapeutic drug that is useful for treating aneurysm. A medicinal composition for treating and/or preventing aneurysm that comprises at least one of the following agents i) to iii) as an active ingredient. i) An agent ...
|
|
WO/2023/124824A1 |
The present invention relates to a trihydroxymethyl aminomethane salt of a compound (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-
bipyridine]-1'(2'H)-yl)methyl)-1-(oxetane-2-ylmethyl)-1H thieno[2,3-d]imidazole-5-carboxylic...
|
|
WO/2023/127805A1 |
In the production of crops in agriculture, horticulture, and the like, the occurrence of damage by pests and the like has been still a major issue, and therefore the development of new agricultural/horticultural pesticides has been deman...
|
|
WO/2023/127909A1 |
Provided is a therapeutic drug that is useful for treating arterial aneurysm. The pharmaceutical composition for treating and/or preventing arterial aneurysm comprises at least one of the following chemical agents i) to iii) as an acti...
|
|
WO/2023/120358A1 |
The present invention addresses the problem of providing a production method with which a condensed ring compound can be obtained at good yield. The present invention relates to a production method for a compound (II) represented by form...
|
|
WO/2023/118092A1 |
The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
|
|
WO/2023/122298A1 |
This invention provides protein stabilizing compounds that have a USP28 Targeting Ligand or USP25 Targeting Ligand, a Protein Targeting Ligand, and optionally a Linker, wherein the Target Protein is ubiquitinated. The protein stabilizing...
|
|
WO/2023/116866A1 |
A five- and six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory...
|
|
WO/2023/120359A1 |
The present invention addresses the problem of providing a compound which reduces the dark current. The present invention relates to a compound which is represented by formula (I). (I): A1-P-A2 (In formula (I), each of A1 and A2 indepe...
|
|
WO/2023/119210A1 |
The present invention relates to a compound as an RIPK1 inhibitor, a stereoisomer thereof, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and a pharmaceutical composition comprisi...
|
|
WO/2023/114954A1 |
Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.
|
|
WO/2023/110869A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2023/109912A1 |
Provided are compounds as well as their compositions and methods of use. The compounds disclosed herein modulate, eg., antagonize, stimulator of interferon genes (STING) activity and are useful in the treatment of various inflammatory di...
|
|
WO/2023/108602A1 |
Disclosed are an intermediate of edoxaban tosylate and a preparation method therefor, having the advantages that the preparation process is simple, reaction conditions are mild, the cost is low, and raw materials are easy to obtain. The ...
|
|
WO/2023/109158A1 |
Disclosed in the present invention is a 7-methylthiazolo[5,4-d]pyrimidine compound, and a preparation method therefor and the use thereof. The compound comprises a compound represented by formula (I) or a physiologically acceptable salt ...
|
|
WO/2023/110138A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/114822A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/104209A1 |
Provided are a class of METTL3 inhibitor compounds and a use thereof in preparation of a medication for inhibiting METTL3, thereby providing a new option for clinically selecting and/or preparing a medication for a disease related to MET...
|
|
WO/2023/103898A1 |
Provided is a novel compound having a macrocyclic structure. Specifically, provided are a compound having a macrocyclic structure of formula (I), or a pharmaceutically acceptable salt or a deuterated form thereof, and a method for prepar...
|
|
WO/2023/106405A1 |
Provided is a compound which can be advantageously used as an organic semiconductor material and has satisfactory solubility in solvents. An organic semiconductor material including such compound is provided. An organic electronic device...
|
|
WO/2023/104195A1 |
Provided is a preparation method for an isothiazolo[5,4-d]pyrimidine IRAK4 inhibitor, particularly relating to a preparation method for the compound of formula (I) and an intermediate compound 6 thereof. The method for obtaining the tran...
|
|
WO/2023/107723A2 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, di...
|
|
WO/2023/098740A1 |
The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
|
|
WO/2023/100942A1 |
[Problem] To develop an artificial catalyst capable of inhibiting aggregation of pathogenic amyloids (tau amyloids) formed by the aggregation of tau proteins, and to provide a prophylactic and therapeutic medicine for amyloid-related dis...
|
|
WO/2023/100844A1 |
The present invention addresses the problem of reducing a dark current. The present invention relates to a compound represented by formula (I). (I): A1―P―A2 (In formula (I), each of A1 and A2 is independently an electron-withdrawin...
|
|
WO/2023/102507A1 |
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-I and are capable of inhibiting the interaction of PD-I with PD-LI. These macrocyclic compounds exhibit in vitro immunomodulatory effic...
|
